Yes, it’s a product-based company. They have a consulting division which is service based. They also have a lot of data offerings which are products clients can purchase: Onekey, DDD, etc. For the life sciences and healthcare sectors, IQVIA is a top worldwide supplier of clinical research services, business insights, and healthcare intelligence. In order to provide actionable insights and services based on superior health data, advanced analytics, healthcare-grade AITM, the newest technologies, and in-depth subject knowledge, IQVIA Connected Intelligence TM powers its portfolio of solutions.

Here is a Quick Overview of IQVIA

Company History

The American company IQVIA Holdings, Inc. is headquartered in Durham, North Carolina, and focuses on clinical research and health information technology. The business is divided into three divisions: Technology & Analytics (40 percent of 2024 revenues), which focuses on health information technology; Research & Development (55 percent of 2024 revenues), which is a contract research firm that manages clinical trials in all their facets; and Contract Sales & Medical (five percent of 2024 revenues), which provides patient engagement services and contract sales to healthcare providers.

Current Status

IQVIA is committed to accelerating the development and commercialization of cutting-edge medical treatments to assist improve patient outcomes and population health worldwide. It employs about 88,000 people in over 100 nations, including specialists in healthcare, data science, life sciences, technology, and operational excellence. IQVIA is a world leader in safeguarding the privacy of individual patients. While producing and analyzing data on a scale that assists healthcare stakeholders in identifying disease patterns and correlating with the precise treatment path and therapy required for better outcomes, the company employs a wide range of privacy-enhancing technologies and safeguards to protect individual privacy.

Future Outlook

It is anticipated that IQVIA Holdings will increase revenue and earnings by 5.8% and 12.6% year, respectively. It is anticipated that EPS will increase by 13% annually. In three years, a return on equity of 26.7% is anticipated. In an effort to improve healthcare, IQVIA’s insights and execution capabilities assist biotech, pharmaceutical, medical device, and government organizations, medical researchers, payers, along with additional stakeholders in the healthcare industry in gaining a better understanding of diseases, human behavior, and scientific advancements.